Soft-tissue repair treatment developer Embody announced that it has landed a $2.5 million grant from the Defense Advanced Research Projects Agency (DARPA). The latest DARPA funding brings Norfolk, Va.-based Embody’s total DARPA non-dilutive funding to nearly $14.4 million, according to a news release. Embody plans to use the Phase II Small Business Innovation Research (SBIR) […]
The FDA granted an investigational device exemption for the 1st-in-human trial of a neural-enabled prosthetic hand developed at Florida International University, backed by more than $2 million from the U.S. Defense Dept. The device is designed to stimulate nerves in the arm to provide sensation during use. It’s billed as the 1st fully implantable, wirelessly controlled Class-III […]
A new robotic hand developed by the Defense Advanced Research Projects Agency has developed a prosthetic hand that allows its user to feel physical sensations. A 28-year-old man with paralyzation due to a spinal cord injury was equipped with the prosthesis, becoming the 1st person to “feel” touch-sensations through the prosthetic unit which is directly connected […]
The U.S. Defense Dept. awarded a 57-month contract worth nearly $7 million to Dean Kamen’s Deka Innovative Solutions for the sensorized prosthetic arm Deka developed. The Deka arm is the 1st prosthetic arm to translate muscle signals into action that’s approved for the U.S. market. The device won de novo approval from the FDA in May […]
Tasso said it won a $2.9 million grant from the U.S. Defense Advanced Research Projects Agency to continue work on an integrated blood-sampling device that can be used in war zones.
The grant to Tasso and development partner GenTegra was awarded based on progress the companies have made under a previously issued Phase II SBIR contract, Madison, Wis.-based Tasso said.
Epilepsy treatment devices maker NeuroPace hopes to expand its clinical applications by supporting a research initiative to evaluate neurostimulation implants in treatment of memory deficits.
Watertown, Mass.-based Arsenal Medical received a $15.5 million Phase II contract from the Defense Advanced Research Projects Agency to support its wound management product.
The foam-based product could help combat medics control hemorrhaging in the intact abdominal cavity and reduce battlefield mortality, a large percentage of which is caused by internal bleeding from abdominal injuries, according to a press release.